This skin problem linked to higher risk for non-alcoholic fatty liver disease

Credit: CC0 Public Domain

Scientists from the First Affiliated Hospital of Shantou University found that Psoriasis is linked to nonalcoholic fatty liver disease (NAFLD) in a U.S. outpatient population.

The research is published in JAMA Dermatology and was conducted by Zhijie Ruan et al.

Psoriasis is a skin disease that causes a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk and scalp.

Psoriasis is a common, long-term (chronic) disease with no cure. It can be painful, interfere with sleep and make it hard to concentrate.

Psoriasis is thought to be an immune system problem. Triggers include infections, stress and cold. The most common symptom is a rash on the skin, but sometimes the rash involves the nails or joints.

The accumulation of liver fat in people who drink little or no alcohol.

The cause of NAFLD is unknown. Risk factors include obesity, gastric bypass surgery, high cholesterol and type 2 diabetes.

Most people have no symptoms. In rare cases, people may experience fatigue, pain or weight loss. Over time, inflammation and scarring of the liver (cirrhosis) can occur.

In the study, the team used data from 5,672 U.S. adults (aged 20 to 59 years) in the National Health and Nutrition Examination Survey.

The researchers found that those with psoriasis had a higher prevalence of NAFLD (32.7 versus 26.6 percent) compared with participants without psoriasis.

The team also found psoriasis was linked to NAFLD among men, among those aged 20 to 39 years, and among those without diabetes.

The team suggests that the association between psoriasis and NAFLD in U.S. adults may be worth considering in psoriasis management.

If you care about liver health, please read studies that people with diabetes need to prevent this dangerous liver disease and 5 big myths about liver detoxing you should know.

For more information about liver health, please see recent studies about oral diseases linked to a 75% increase in liver cancer risk, and results showing a new way to treat chronic liver disease.

Copyright © 2022 Knowridge Science Report. All rights reserved.